Showing 4641-4650 of 6946 results for "".
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- Analysis: Dermoscopy Raises Diagnostic Odds for Melanoma Accuracyhttps://practicaldermatology.com/news/analysis-dermoscopy-raises-diagnostic-odds-melanoma-accuracy/2468666/Experienced dermatologists achieve significantly higher diagnostic accuracy for skin cancer than primary care physicians (PCPs), particularly when using dermoscopy, according to a new meta-analysis of 100 studies. The review, published in JAMA Dermatology, focused on diagnostic accuracy fo
- Study Links Skin Microbiota and AD Alleviation via Melatoninhttps://practicaldermatology.com/news/study-links-skin-microbiota-and-ad-alleviation-melatonin/2468664/A new study published in the Journal of Allergy and Clinical Immunology indicates melatonin has been shown to reduce atopic dermatitis (AD) symptoms by altering skin microbiota composition, with short-chain fatty acids (SCFAs) such as propionic acid playing a key role in this process. Alth
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro